A5091661570- Immunotherapy and Immune Responses
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- vaccines and immunoinformatics approaches
- T-cell and B-cell Immunology
- Genetic factors in colorectal cancer
- Cancer Research and Treatments
- HER2/EGFR in Cancer Research
- Cytomegalovirus and herpesvirus research
- Medical research and treatments
- Occupational Health and Safety in Workplaces
- Atherosclerosis and Cardiovascular Diseases
- Single-cell and spatial transcriptomics
- Health and Lifestyle Studies
- Statistical Methods in Clinical Trials
- Educational Practices and Sociocultural Research
- RNA modifications and cancer
- Genetics, Aging, and Longevity in Model Organisms
- Colorectal Cancer Treatments and Studies
Center of Molecular Immunology (Cuba)
2013-2025
Hospital Universitario Dexeus
2019-2020
Applied Mathematics (United States)
2013
Hermanos Ameijeiras Hospital
2008
We show the result of a randomized phase II clinical trial with an epidermal growth factor (EGF)-based cancer vaccine in advanced non-small-cell lung (NSCLC) patients, evaluating immunogenicity, safety, and effect on survival.Eighty patients stage IIIB/IV NSCLC after finishing first-line chemotherapy were randomly assigned to receive best supportive care or EGF vaccinations.Vaccination was safe. Adverse events observed less than 25% cases grade 1 2 according National Cancer Institute Common...
EGFR is a well-validated target for patients with non-small cell lung cancer (NSCLC). CIMAvax-EGF therapeutic vaccine composed of human recombinant EGF conjugated to carrier protein and Montanide ISA51 as adjuvant. The intended induce antibodies against self EGFs that block EGF-EGFR interaction.To evaluate overall survival, safety, immunogenicity, concentration in serum after CIMAvax-EGF, randomized phase III trial was done advanced NSCLC. Four 6 weeks first-line chemotherapy, 405 stage...
Abstract Purpose: Epidermal growth factor (EGF) might be a suitable immunotherapeutic target in non–small-cell lung cancer (NSCLC). Our approach consists of active immunotherapy with EGF. The aim the study is to characterize humoral response and its effects on signal transduction relation clinical outcome. Experimental Design: Eighty NSCLC patients treated first-line chemotherapy were randomized receive EGF vaccine or supportive care. concentration sera, anti-EGF antibodies their capacity...
An epidermal growth factor (EGF) vaccine was given before and after standard first line chemotherapy to patients with advanced nonsmall cell lung cancer (NSCLC), investigate the immunologic clinical results in a phase 1 study. Twenty diagnosed NSCLC were recruited. Two vaccinations of treatment, subsequent monthly vaccination concluding chemotherapy. The EGF dose increased compared previous trials; primary end points immunogenicity safety. Anti-EGF antibody titers more than 20 times higher...
Immunosenescence is a dynamic process, where both genetic and environmental factors account for the substantial inter-individual variability. This paper integrates all data on immunosenescence markers generated in our laboratory describes differences and/or similarities between individuals based their biological conditions (immunosenescence markers) associations with chronological age health status. The dataset consisted of immunological from healthy donors, centenarians, patients diagnosed...
Epidermal Growth Factor (EGF) promotes tumor cell proliferation and survival upon binding to its receptor. We have developed a new active specific immunotherapy based on EGF deprivation. In the present paper, we show results of Phase I trial in 43 patients with advanced non-small lung cancer (NSCLC) who received vaccine. Patients had already first line therapy were randomized receive single or double dose vaccine, weekly for four weeks monthly thereafter. No significant toxicity was seen...
Epidermal growth factor receptor (EGFR) is frequently overexpressed in epithelial tumors and associated with a poor prognosis. An increasing interest developing anti-EGFR therapies has resulted the evaluation of monoclonal antibodies capacity to bind EGFR, inhibiting EGFR-dependent cellular transformation. A differential toxicity therapeutic effect vivo are affinity isotype molecule. In this study, we examined biological activities three (MAbs)—Ior egf/r3 (mouse IgG2a, 10−9 M), Nimotuzumab...
The prognosis of patients with advanced non small cell lung (NSCLC) cancer remains dismal. Epidermal Growth Factor Receptor is over-expressed in many epithelial derived tumors and its role the development progression NSCLC widely documented. CimaVax-EGF a therapeutic vaccine composed by human recombinant (EGF) conjugated to carrier protein, P64K from Neisseria Meningitides. intended induce antibodies against self EGF that would block EGF-EGFR interaction. has been evaluated so far more than...
The progressive decline in the immune function during ageing is termed immunosenescence. Previous studies have reported differences between males and females distribution cell responses of lymphocyte subsets. Most immunosenescence been done populations industrialized countries living a rather cold environment, facing lower antigenic challenges such as Cytomegalovirus (CMV). aim this study was to determine effect on lymphocytes population with high prevalence CMV infection all ages, compare...
With the advent of precision oncology, liquid biopsies are quickly gaining acceptance in clinical setting. However, some cases, amount DNA isolated is insufficient for Next-Generation Sequencing (NGS) analysis. The nCounter platform could be an alternative, but it has never been explored detection clinically relevant alterations fluids.Circulating-free (cfDNA) was purified from blood, cerebrospinal fluid, and ascites patients with cancer analyzed 3 D Single Nucleotide Variant (SNV) Solid...
We previously reported that CIMAvax-EGF vaccine is safe, immunogenic and efficacious to treat advanced non-small-cell lung cancer (NSCLC) patients. A phase III trial was designed using an optimized immunization schedule. It included higher antigen dose injections at multiple sites. Immune response circulating biomarkers were studied in a subset of EGF-specific antibody titers, IgG subclasses, peptide immunodominance assessed by ELISA. In vitro EGF-neutralization capacity immune sera EGF-IgG...
3013 Background: EGFR is overexpressed in many epithelial tumors. EGF one of the most important growth factors that stimulates EGFR, a paracrine way. CIMAvax-EGF therapeutic cancer vaccine intended to induce antibodies against EGF. It composed by recombinant conjugated P64 from N.Meningitides as carrier and Montanide, adjuvant. Methods: Two controlled trials were done advanced NSCLC castration-resistant prostate patients (CRPC). A multicentric, randomized Phase III trial was designed assess...
2527 Background: The prognosis of patients with advanced non small cell lung cancer (NSCLC) remains dismal. Epidermal Growth Factor Receptor (EGFR) is overexpressed in epithelial tumors and its role the development NSCLC widely proven. EGF vaccine a therapeutic composed by recombinant (EGF) conjugated to carrier protein, P64K from Neisseria Meningitides Montanide, as adjuvant. intended induce antibodies against self that would block EGF-EGFR interaction. Methods: A multicentric, randomized...
2548 Background: During the last 10 years we have studied effect of vaccination against self EGF, both in preclinical setting, and several pilot clinical trials advanced non-small cell lung cancer (NSCLC) patients. Here, undertake analysis aggregated data from these trials, addressing particularly issue relationship between immunization survival. Methods: Pooled 3 75 patients, considered not amenable to any other modality onco-specific treatment, were used. For survival analysis, 27 NSCLC...
Background: The Center of Molecular Immunology (CIM) is a center in Cuba devoted to the research, development and manufacturing biotechnological products. CIMAvax?EGF vaccine for treatment non-small cell lung cancer patients (NSCL). Purpose: aim this work evaluate effects some potential prognostic factors on overall survival treated with vaccine, based data collected phase II III clinical trials. Methods: stratified Cox regression model used these factors, separate analysis each trial,...